Michael Eissenstat
No más puestos en curso
Perfil
Michael Eissenstat worked as Vice President-Chemistry at Sequoia Pharmaceuticals, Inc., Principal at Tibotec Virco NV, and Principal at Sterling Winthrop Pharmaceuticals Research Center.
He holds a doctorate degree from Harvard University.
Antiguos cargos conocidos de Michael Eissenstat.
Empresas | Cargo | Fin |
---|---|---|
Sterling Winthrop Pharmaceuticals Research Center | Corporate Officer/Principal | - |
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Corporate Officer/Principal | - |
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Corporate Officer/Principal | - |
Formación de Michael Eissenstat.
Harvard University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 3 |
---|---|
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
Sterling Winthrop Pharmaceuticals Research Center | |
Tibotec Virco NV
Tibotec Virco NV Miscellaneous Commercial ServicesCommercial Services Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium. | Commercial Services |
- Bolsa de valores
- Insiders
- Michael Eissenstat